We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“There is a knowledge explosion in medicine today, which can overwhelm the clinician. This is particularly true in the area of valvular heart disease, in which multiple investigational trials are being rapidly performed and released, so that it becomes extremely difficult for an individual clinician to keep up with optimal treatments for each specific patient. The Valvular Heart Disease Guideline brings together experts in the field who review all the data and arrive at a consensus opinion for best treatment, outlined in the class recommendations.”
“Current research and new technology continue to transform the treatment of heart valve disease, as updated lifestyle and medication guidance evolve and less invasive procedures have replaced traditional surgery for many patients.”
“The publication of the 2020 ACC/AHA guidelines for the management of patients with heart valve disease, while updating essential steps for clinical evaluation and diagnosis, and assessing the impact of new data, faces both methodological issues and conflict of interest, downplaying a crescendo body of evidence for adverse outcomes associated with transcatheter therapies, aggravated by the manifest conflict of interest of the writing committee authors and reviewers included in the final version of the document.”
No takes yet. Share an insight, caveat, or question.
Otto et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: